New insider activity at Keros Therapeutics ( (KROS) ) has taken place on October 15, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Significant shareholder ADAR1 Capital Management, LLC has made a substantial move by selling 5,389,264 shares of Keros Therapeutics stock, amounting to a total sale value of $95,659,436.
Recent Updates on KROS stock
In the last 24 hours, Keros Therapeutics announced a $375 million capital return program, including a significant share repurchase from ADAR1 Capital Management and Pontifax Venture Capital, reflecting confidence in its financial position and clinical strategy, particularly for its KER-065 program. The company also plans to distribute part of its Takeda licensing revenue to shareholders to enhance long-term stockholder value. The resignations of board members Tomer Kariv and Ran Nussbaum were announced, with Jean-Jacques Bienaimé appointed as the new Chair of the Nominating and Corporate Governance Committee. Despite strong financial performance, mixed technical indicators and a high P/E ratio suggest potential overvaluation, leading to a Hold rating with a $16.00 price target.
Spark’s Take on KROS Stock
According to Spark, TipRanks’ AI Analyst, KROS is a Neutral.
Keros Therapeutics’ overall score is driven by its strong financial performance, particularly its profitability and balance sheet strength. However, technical indicators suggest mixed signals, and the high P/E ratio indicates potential overvaluation. The absence of earnings call data and corporate events limits further insights.
To see Spark’s full report on KROS stock, click here.
More about Keros Therapeutics
YTD Price Performance: -5.21%
Average Trading Volume: 437,780
Technical Sentiment Signal: Sell
Current Market Cap: $645.4M